UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.237

Sortiert nach

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Nature reviews. Drug discovery, 2020-03, Vol.19 (3), p.149-150

2020

Volltextzugriff (PDF)

Approved Antiviral Drugs over the Past 50 Years

Clinical microbiology reviews, 2016-07, Vol.29 (3), p.695-747

2016

Volltextzugriff (PDF)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

Antiviral Chemistry and Chemotherapy, 2019-01, Vol.27, p.2040206619829382-2040206619829382

De Clercq, Erik

2019

Volltextzugriff (PDF)

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Biochemical pharmacology, 2016-11, Vol.119, p.1-7

De Clercq, Erik

2016

Volltextzugriff (PDF)

Highlights in Antiviral Drug Research: Antivirals at the Horizon

Medicinal research reviews, 2013-11, Vol.33 (6), p.1215-1248

Clercq, Erik De

2013

Volltextzugriff (PDF)

Acyclic nucleoside phosphonates: a key class of antiviral drugs

Nature reviews. Drug discovery, 2005-11, Vol.4 (11), p.928-940

2005

Volltextzugriff (PDF)

Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses

Antiviral chemistry & chemotherapy, 2018, Vol.26, p.2040206618761299

2018

Volltextzugriff (PDF)

Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives

Molecules (Basel, Switzerland), 2007-08, Vol.12 (8), p.1720-1730

2007

Volltextzugriff (PDF)

Selective Anti-Herpesvirus Agents

Antiviral Chemistry and Chemotherapy, 2013-06, Vol.23 (3), p.93-101

De Clercq, Erik

2013

Volltextzugriff (PDF)

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV

International journal of antimicrobial agents, 2009-04, Vol.33 (4), p.307-320

De Clercq, Erik

2009

Volltextzugriff (PDF)

Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators

Molecules (Basel, Switzerland), 2022-11, Vol.27 (21), p.7640

2022

Volltextzugriff (PDF)

Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective

Biomedicines, 2021-04, Vol.9 (4), p.412

2021

Volltextzugriff (PDF)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Antiviral research, 2017-06, Vol.142, p.83-122

2017

Volltextzugriff (PDF)

Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors

European journal of medicinal chemistry, 2021-12, Vol.226, p.113848-113848, Article 113848

2021

Volltextzugriff (PDF)

The design of drugs for HIV and HCV

Nature reviews. Drug discovery, 2007-12, Vol.6 (12), p.1001-1018

Clercq, Erik De

2007

Volltextzugriff (PDF)

The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)

Biochemical pharmacology, 2009-06, Vol.77 (11), p.1655-1664

De Clercq, Erik

2009

Volltextzugriff (PDF)

Current race in the development of DAAs (direct-acting antivirals) against HCV

Biochemical pharmacology, 2014-06, Vol.89 (4), p.441-452

De Clercq, Erik

2014

Volltextzugriff (PDF)

New anti-HIV agents and targets

Medicinal research reviews, 2002-11, Vol.22 (6), p.531-565

Clercq, Erik De

2002

Volltextzugriff (PDF)

Structure−Activity Relationship of New Anti-Hepatitis C Virus Agents: Heterobicycle−Coumarin Conjugates

Journal of medicinal chemistry, 2009-03, Vol.52 (5), p.1486-1490

2009

Volltextzugriff (PDF)

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Molecules (Basel, Switzerland), 2022-11, Vol.27 (21), p.7538

2022

Volltextzugriff (PDF)

Ebola virus (EBOV) infection: Therapeutic strategies

Biochemical pharmacology, 2015-01, Vol.93 (1), p.1-10

De Clercq, Erik

2015

Volltextzugriff (PDF)

Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?

Journal of medicinal chemistry, 2010-01, Vol.53 (2), p.521-538

2010

Volltextzugriff (PDF)

The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond

Biochemical pharmacology, 2011-07, Vol.82 (2), p.99-109

De Clercq, Erik

2011

Volltextzugriff (PDF)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future

Chemistry & biodiversity, 2004-01, Vol.1 (1), p.44-64

De Clercq, Erik

2004

Volltextzugriff (PDF)

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends

Journal of medicinal chemistry, 2016-04, Vol.59 (7), p.2849

2016

Volltextzugriff (PDF)

1 – 25 von 2.237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.983)
Mit Volltextzugriff
(2.103)

Publikationsform

Artikel
(2.180)
Buchkapitel
(50)
Bücher
(6)
Webseiten
(1)

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.555)
Life Sciences & Biomedicine
(1.445)
Humans
(1.050)
Pharmacology & Pharmacy
(900)
Biological And Medical Sciences
(726)
Medical Sciences
(645)
Animals
(614)
Chemistry, Medicinal
(614)
Pharmacology. Drug Treatments
(602)
Antiviral Agents
(572)
Antiviral Agents - Pharmacology
(548)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(510)
Structure-Activity Relationship
(479)
Cell Line
(446)
Hiv-1 - Drug Effects
(401)
Chemistry
(389)
Biochemistry & Molecular Biology
(378)
Anti-Hiv Agents - Pharmacology
(331)
Aids/hiv
(306)
Antiviral Agents - Chemical Synthesis
(300)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Approved Antiviral Drugs over the Past 50 Years

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Highlights in Antiviral Drug Research: Antivirals at the Horizon

Acyclic nucleoside phosphonates: a key class of antiviral drugs

Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses

Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives

Selective Anti-Herpesvirus Agents

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV

Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators

Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors

The design of drugs for HIV and HCV

The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)

Current race in the development of DAAs (direct-acting antivirals) against HCV

New anti-HIV agents and targets

Structure−Activity Relationship of New Anti-Hepatitis C Virus Agents: Heterobicycle−Coumarin Conjugates

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Ebola virus (EBOV) infection: Therapeutic strategies

Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?

The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends

Suchergebnisse filtern